Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ambitious AB Science Gets Masitinib Win For Severe Asthma

Drug In Trials For Seven Indications

Executive Summary

Plagued by concerns on the integrity of data and compliance issues with its clinical practices, the French firm still believes masitinib could be effective for ALS, multiple sclerosis, cancers, asthma and even Alzheimer's.

You may also be interested in...



AB Science’s Masitinib/Docetaxel Benefits In Advanced Prostate Cancer

AB Science’s top-line results from a Phase III study suggest its lead candidate masitinib may be of benefit when combined with docetaxel chemotherapy in patients with early metastatic castration-resistant prostate cancer.

Tech Transfer Roundup: BridgeBio’s R&D Efforts Span New Seven New Agreements

Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.

Problems With Drug Absorption Studies Still ‘Relatively Common’ In EU

A retrospective analysis of new drugs evaluated by the European Medicines Agency since 2010 shows that a lack of, or major deficiencies in, human mass balance studies is still a concern in regulatory submissions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC126168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel